全文获取类型
收费全文 | 48646篇 |
免费 | 4323篇 |
国内免费 | 5628篇 |
出版年
2024年 | 121篇 |
2023年 | 685篇 |
2022年 | 1715篇 |
2021年 | 2735篇 |
2020年 | 2041篇 |
2019年 | 2439篇 |
2018年 | 2228篇 |
2017年 | 1685篇 |
2016年 | 2301篇 |
2015年 | 3265篇 |
2014年 | 3865篇 |
2013年 | 3949篇 |
2012年 | 4714篇 |
2011年 | 4200篇 |
2010年 | 2611篇 |
2009年 | 2406篇 |
2008年 | 2654篇 |
2007年 | 2172篇 |
2006年 | 1927篇 |
2005年 | 1594篇 |
2004年 | 1459篇 |
2003年 | 1354篇 |
2002年 | 1126篇 |
2001年 | 937篇 |
2000年 | 774篇 |
1999年 | 691篇 |
1998年 | 432篇 |
1997年 | 353篇 |
1996年 | 350篇 |
1995年 | 292篇 |
1994年 | 228篇 |
1993年 | 193篇 |
1992年 | 225篇 |
1991年 | 208篇 |
1990年 | 169篇 |
1989年 | 112篇 |
1988年 | 81篇 |
1987年 | 86篇 |
1986年 | 50篇 |
1985年 | 61篇 |
1984年 | 29篇 |
1983年 | 34篇 |
1982年 | 19篇 |
1981年 | 5篇 |
1980年 | 7篇 |
1979年 | 3篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1974年 | 2篇 |
1950年 | 2篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
32.
33.
Xiao Zhang Jinpeng Li Bo Yang Qina Leng Ji Li Xintuan Wang Junyao Lu Opeyemi Joshua Olatunji Jian Tang 《化学与生物多样性》2021,18(5):e2100065
This study investigated the protective effects of two polysaccharides (CPA-1 and CPB-2) from Cordyceps cicadae against high fructose/high fat diet (HF/HFD) induced obesity and metabolic disorders in rats. Rats were either fed with normal diet or HF/HFD and treated with CPA-1 and CPB-2 (100 and 300 mg/kg) for 11 weeks. Administration of CPA-1 and CPB-2 significantly and dose dependently reduced body and liver weight, insulin and glucose tolerance, serum insulin and glucose levels. Furthermore, serum and hepatic lipid profiles, liver function enzymes and proinflammatory cytokines (TNF-α, IL-1β and IL-6) were markedly reduced. Additionally, CPA-1 and CPB-2 treatment alleviated hepatic oxidative stress by reducing lipid peroxidation level (MDA) and upregulating glutathione peroxidase (GSH-Px), superoxide dismutase (SOD) and catalase (CAT) activities as well as ameliorated histological alterations through the reduction of hepatic lipid accumulation. These results suggested that the polysaccharides from C. cicadae showed protective effects against HF/HFD induced metabolic disturbances and may be considered as a dietary supplement for treating obesity. 相似文献
34.
35.
Xiaoqing Wu Xiaorui Xie Linjuan Su Na Lin Bin Liang Nan Guo Qingquan Chen Liangpu Xu Hailong Huang 《Journal of cellular and molecular medicine》2021,25(18):8929-8935
Pallister-Killian syndrome (PKS) is a rare sporadic genetic disorder usually caused by mosaicism of an extra isochromosome of 12p (i(12p)). This retrospective study analysed the prenatal ultrasound manifestations and molecular and cytogenetic results of five PKS foetuses. Samples of amniotic fluid and/or cord blood, skin biopsy and placenta were collected. Conventional karyotyping and single nucleotide polymorphism array (SNP array) were performed on all the amniotic fluid or cord blood samples. Copy number variants sequencing (CNV-seq) and fluorescence in situ hybridization (FISH) were also used for the validation for one foetus. All the five foetuses were from pregnancies with advanced parental age. Two foetuses involved structural abnormalities and one foetus had only soft markers, all of which included increased nuchal translucency. The rest two foetuses had normal ultrasounds in the second trimester, which has rarely been reported before. The karyotype revealed typical i(12p) in four cases and a small supernumerary marker chromosome consisting of 12p and 20p in the remaining one case. The proportion of cells with i(12p) ranged from 0 to 100% in cultural cells, while SNP array results suggested 2−4 copies of 12p. For one foetus, metaphase FISH showed normal results, but the interphase FISH suggested cell lines with two, three and four copies of 12p in the amniotic fluid. Advanced parental age may be an important risk factor for PKS, and there were no typical ultrasound manifestations related to PKS. A combination of karyotype analysis and molecular diagnosis is an effective method for the diagnosis of PKS. 相似文献
36.
37.
Wei Liu Yaoting Sun Weigang Ge Fangfei Zhang Lin Gan Yi Zhu Tiannan Guo Kexin Liu 《Molecular & cellular proteomics : MCP》2022,21(2):100187
Drug resistance is a critical obstacle to effective treatment in patients with chronic myeloid leukemia. To understand the underlying resistance mechanisms in response to imatinib mesylate (IMA) and adriamycin (ADR), the parental K562 cells were treated with low doses of IMA or ADR for 2 months to generate derivative cells with mild, intermediate, and severe resistance to the drugs as defined by their increasing resistance index. PulseDIA-based (DIA [data-independent acquisition]) quantitative proteomics was then employed to reveal the proteome changes in these resistant cells. In total, 7082 proteins from 98,232 peptides were identified and quantified from the dataset using four DIA software tools including OpenSWATH, Spectronaut, DIA-NN, and EncyclopeDIA. Sirtuin signaling pathway was found to be significantly enriched in both ADR-resistant and IMA-resistant K562 cells. In particular, isocitrate dehydrogenase (NADP(+)) 2 was identified as a potential drug target correlated with the drug resistance phenotype, and its inhibition by the antagonist AGI-6780 reversed the acquired resistance in K562 cells to either ADR or IMA. Together, our study has implicated isocitrate dehydrogenase (NADP(+)) 2 as a potential target that can be therapeutically leveraged to alleviate the drug resistance in K562 cells when treated with IMA and ADR. 相似文献
38.
39.
40.
Haiyan Miao Jingjing Lu Yibing Guo Hongquan Qiu Yu Zhang Xihao Yao Xiaohong Li Yuhua Lu 《Journal of cellular and molecular medicine》2021,25(7):3654-3664
Pancreatic ductal adenocarcinoma (PDAC) is an invasive and aggressive cancer that remains a major threat to human health across the globe. Despite advances in cancer treatments and diagnosis, the prognosis of PDAC patients remains poor. New and more effective PDAC therapies are therefore urgently required. In this study, we identified a novel host factor, namely the LncRNA TP73-AS1, as overexpressed in PDAC tissues compared to adjacent healthy tissue samples. The overexpression of TP-73-AS1 was found to correlate with both PDAC stage and lymph node metastasis. To reveal its role in PDCA, we targeted TP73-AS1 using LnRNA inhibitors in a range of pancreatic cancer (PC) cell lines. We found that the inhibition of TP73-AS1 led to a loss of MMP14 expression in PC cells and significantly inhibited their migratory and invasive capacity. No effects of TP73-AS1 on cell survival or proliferation were observed. Mechanistically, we found that TP73-AS1 suppressed the expression of the known oncogenic miR-200a. Taken together, these data highlight the prognostic potential of TP73-AS1 for PC patients and highlight it as a potential anti-PDAC therapeutic target. 相似文献